Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction
Baghban A, Azar MM, Bernardo RM, Malinis M. Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction. BMJ Case Reports 2016, 2016: bcr2016217998. PMID: 27852682, PMCID: PMC5129162, DOI: 10.1136/bcr-2016-217998.Peer-Reviewed Case Reports and Technical NotesConceptsMycobacterium tuberculosisDisseminated Mycobacterium tuberculosisIsoniazid preventative therapyHigh-risk patientsSolid organ transplantsOngoing risk factorsAlemtuzumab inductionDisseminated tuberculosisInduction immunosuppressionPeritransplant periodRenal transplantRenal transplantationPulmonary tuberculosisTuberculosis infectionPreventative therapyRisk factorsOrgan transplantsTuberculosisPatientsTransplantAvailable literatureImmunosuppressionTransplantationUnique challengesTherapyIntegrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs